Eckert & Ziegler, AtomView Sign Agreement for Lutetium-177 Supply

Eckert & Ziegler SE and AtomVie Global Radiopharma Inc. have signed a global supply agreement for Eckert & Ziegler to provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand) to support AtomVie’s CDMO activities for radiopharmaceutical manufacturing.

The collaboration covers both early and late-stage development and extends to global programs. Through this partnership, Atomvie secures reliable access to Theralugand, which will enable further development of Lu-177 based radiopharmaceuticals in their facility. The flexibility of the agreement makes it possible to respond dynamically to the needs of pharmaceutical partners at different stages of radiopharmaceutical development and commercialization, while addressing regulatory requirements worldwide.

“We are happy to support AtomVie in advancing global radiopharmaceutical development programs with Theralugand,” stated Dr Harald Hasselmann, CEO of Eckert & Ziegler SE. “By providing our high-quality radionuclides, we vitally contribute to the further development of therapeutic approaches in nuclear medicine.”

Bruno Paquin, CEO of AtomVie commented “Partnering with Eckert & Ziegler is a significant step in ensuring that our global partners developing Lutetium-177 based radiopharmaceuticals have the support they need. With our new facility set to open later this year, this collaboration enhances our ability to provide reliable, high-quality manufacturing services. Together with our partners, we look forward to further advancing innovation and transforming patients' lives.”